Ryufin

Arjo AB (publ)

Sweden · SE0010468116 · reports in SEK · Europe

The answers

From the annual report for the year to Dec 31, 2024. Each line says what it is based on.

Is it growing?Fair
Revenue +2.8% in the year to Dec 31, 2024, on the year before.
Is it a good business?Fair
It earned 6.0% on its shareholders' equity in the year to Dec 31, 2024.
Is it safe?n/a
No balance sheet tagged in the filing.
Is the price fair?n/a
Not answered: no exchange publishes this company's price for free reuse, so there is no P/E here.

The year

Year to Dec 31, 2024, consolidated, in SEK.

SEK 11.3B

revenue

7.9%

operating margin

SEK 498M

net profit

Year by year

As filed; an earlier year can differ from its own report when the company restated it.

Dec 2021Dec 2022Dec 2023Dec 2024
RevenueSEK 9.1BSEK 10.0BSEK 11.0BSEK 11.3B
Operating profitSEK 1.1BSEK 691MSEK 884MSEK 893M
Net profit to shareholdersSEK 742MSEK 447MSEK 480MSEK 498M
Earnings per shareSEK 2.72SEK 1.64SEK 1.76SEK 1.83
Dividend per sharen/aSEK 1.15n/aSEK 0.90
Cash from operationsSEK 1.7BSEK 915MSEK 2.1BSEK 1.5B
Capital spendingn/an/aSEK 403MSEK 393M
CashSEK 757MSEK 949MSEK 923MSEK 892M
Total assetsSEK 14.6BSEK 16.2BSEK 15.4BSEK 16.3B

What they do

In the company's own words, from the annual report.

Arjo är en global leverantör av medicintekniska produkter och lösningar som genom att skapa möjlighet för ökad mobilitet skapar bättre kliniska och finansiella resultat i vården, och därmed bidrar till ett hållbart sjukvårdssystem. Verksamheten är till största delen förlagd utanför Sverige och Arjos största marknader är USA, Storbritan- nien, Frankrike, Kanada och Tyskland.

Source: the company’s annual financial report in ESEF, via filings.xbrl.org (XBRL International). Listed shares from ESMA’s FIRDS register; ESMA does not endorse this site. Ryufin computed the answers and ratios from the filed figures.